LAROTRECTINIB
larotrectinib 100 mg capsule, 56
LAROTRECTINIB (14282Q)
14282Q
Manner of administration:Oral
Restriction
Indication: Solid tumours (of certain specified types) with confirmed neurotrophic tropomyosin
receptor kinase (NTRK) gene fusion
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 56 | # of repeats: 5 | DPMQ: $10,062.93 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Vitrakvi | |||||